Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.
Myelodysplastic Syndrome
Phase III
Adults
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics
APR-246, Azacitidine
Byrne, Michael
International
Vanderbilt University
06-14-2019
Treatment
VICCHEM18178
NCT03745716

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Signed Informed Consent (ICF) and is able to comply with protocol requirements

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: